



# The gift of life


Improve the odds for your  
transplant patients.

Transplant recipients are vulnerable to infections and reinfections due to the immunosuppressive therapy that is required to prevent organ rejection. To support your transplant patients' needs, we provide *artus*<sup>®</sup> realtime PCR, QuantiFERON<sup>®</sup>-CMV, and QuantiFERON Monitor<sup>®</sup> assays which can assist you in individualizing patient management, and ultimately improve patient care.

Sample to Insight

## Unrivaled solutions, including real-time PCR and IGRA technologies

By offering a broad range of novel, accurate markers for posttransplant patient management, we can make improvements in the life of transplant patients possible (Figure 1).




**Figure 1.** The different assays complement each other and help you give your patient the best potential care.

**Table 1. QIAGEN has recently launched 4 new *artus* assays on the Rotor-Gene Q platform, further strengthening our broad portfolio.**

	<i>artus</i> HadV RG PCR Kit	<i>artus</i> JCV RG-PCR Kit	<i>artus</i> HSV-1/2 Quant RG PCR Kit	<i>artus</i> HHV-6 RG PCR Kit
Kit size	96 reactions	96 reactions	96 reactions	96 reactions
Cat. no.	4530265	4532265	4515265	4521265
LOD (copies/ $\mu$ l eluate)	1.07 (95% CI: 0.59–2.099 copies/ $\mu$ l)	0.033 (95% CI: 0.013–0.175 copies/ $\mu$ l)	HSV-1 specific DNA 0.33 (95% CI: 0.16–1.3 copies/ $\mu$ l) HSV-2 specific DNA 1.2 (95% CI: 0.7–3.5 copies/ $\mu$ l)	HHV-6A-specific DNA 1.46 (95% CI: 0.72–4.57 copies/ $\mu$ l) HHV-6B-specific DNA: 2.58 (95% CI: 1.44–6.30 copies/ $\mu$ l)
Detection	Quantitative	Quantitative	Quantitative	Quantitative
Regulatory status	CE IVD	CE IVD	CE IVD	CE IVD
Rotor-Gene Q instrument	✓	✓	✓	✓

## Fully automated diagnostic solutions

All of our Transplantation associated products complement the broad assay menu validated on the CE-IVD QIASymphony RGQ workflow.



Panel	Pathogen	Detection method
<b>Blood Borne Viruses</b>	HIV, HBV, HCV	Quantitative
<b>Womens Health/ Sexually Transmitted Infections</b>	CT/NG, GBS, <i>T. vaginalis</i> *	Qualitative
<b>Healthcare Associated Infections</b>	<i>C. difficile</i> , VanR, MRSA/SA	Qualitative
<b>Respiratory Screen</b>	22 virus and bacteria targets	Qualitative
<b>Open Channel</b>	Flexible utility for in-house assays	

\* Coming soon.

## Complement your *artus* real-time PCR assays with QIAGEN immune-monitoring solutions

Transplant patients face the possibility of debilitating infections that can result from immunosuppressive therapy, and viral load assays may not tell the whole story of a patient's immune-status. To complement our *artus* real-time PCR assays, QIAGEN offers QuantiFERON-CMV and QuantiFERON Monitor, two immune monitoring solutions that measure your patient's immune responses using simple whole blood samples. QuantiFERON-CMV measures IFN- $\gamma$  responses to CMV antigens in your transplant recipients which may help predict the development of late-onset CMV disease (1-8). QuantiFERON Monitor measures IFN- $\gamma$  responses to innate and adaptive immune stimulants as a proxy for your patient's overall immune status, which may allow the tailoring of immunosuppression and prophylaxis based on an individual's risk of infection.

---

#### References:

1. Kumar, D. et al. (2009) Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. *Am. J. Transplant.* **9**, 1214.
2. Lumberas C, Manuel O, Len O, ten Berge IJ, Sgarabotto D, Hirsch HH (2014) Cytomegalovirus infection in solid organ transplant recipients. *Clin Microbiol Infect.* **20**, 19–26
3. Westall, G.P. et al. (2008) Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV reactivation following lung transplantation by measuring CMV-specific CD8<sup>+</sup> T cell immunity. *Am. J. Transplant.* **8**, 1749.
4. Fleming, T. et al. (2010) Ex vivo monitoring of human cytomegalovirus-specific CD8<sup>+</sup> T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish Hospital. *J. Med. Virol.* **82**, 433.
5. Lisboa, L.F. et al. (2012) Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. *Am. J. Transplant.* **93**, 195.
6. Weseslindtner, L. et al. (2012) *Am. J. Transplant.* Prospective analysis of human cytomegalovirus DNAemia and specific CD8<sup>+</sup> T-cell responses in lung transplant recipients. **12**, 2172.
7. Manuel, O. et al. (2013) Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. *Clin. Infect. Dis.* **56**, 817.
8. Fernández-Ruiz M, Kumar D, Humar A (2014) Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. *Clin Transl. Immunol* doi: 10.1038/cti.2014.3

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at [www.qiagen.com](http://www.qiagen.com) or can be requested from QIAGEN Technical Services or your local distributor. Regulatory requirements vary by country, products may not be available in your geographic area.

Trademarks: QIAGEN®, Sample to Insight®, QIASymphony®, *artus*®, QuantiFERON®, Rotor-Gene® (QIAGEN Group). Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

PROM-9451-001 1101180 03/2016 © 2016 QIAGEN, all rights reserved.

Ordering [www.qiagen.com/contact](http://www.qiagen.com/contact) | Technical Support [support.qiagen.com](mailto:support.qiagen.com) | Website [www.qiagen.com](http://www.qiagen.com)